Overview

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: - CD79b-19 CAR T cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Phase:
Phase 1
Details
Lead Sponsor:
Marcela V. Maus, M.D.,Ph.D.
Treatments:
Cyclophosphamide
Fludarabine